These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15650696

  • 1. Comparative analysis of intracellular trans-splicing ribozyme activity against hepatitis C virus internal ribosome entry site.
    Ryu KJ, Lee SW.
    J Microbiol; 2004 Dec; 42(4):361-4. PubMed ID: 15650696
    [Abstract] [Full Text] [Related]

  • 2. Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation.
    Krüger M, Beger C, Welch PJ, Barber JR, Manns MP, Wong-Staal F.
    Mol Cell Biol; 2001 Dec; 21(24):8357-64. PubMed ID: 11713272
    [Abstract] [Full Text] [Related]

  • 3. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons.
    Jarczak D, Korf M, Beger C, Manns MP, Krüger M.
    FEBS J; 2005 Nov; 272(22):5910-22. PubMed ID: 16279954
    [Abstract] [Full Text] [Related]

  • 4. Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing.
    Ryu KJ, Kim JH, Lee SW.
    Mol Ther; 2003 Mar; 7(3):386-95. PubMed ID: 12668134
    [Abstract] [Full Text] [Related]

  • 5. Identification of the most accessible sites to ribozymes on the hepatitis C virus internal ribosome entry site.
    Ryu KJ, Lee SW.
    J Biochem Mol Biol; 2003 Nov 30; 36(6):538-44. PubMed ID: 14659071
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.
    Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA, Blatt LM.
    Hepatology; 2000 Mar 30; 31(3):769-76. PubMed ID: 10706571
    [Abstract] [Full Text] [Related]

  • 7. [Reconstruction of hepatitis D virus ribozymes and their ability to trans-cleave hepatitis C virus RNA].
    Yu Y, Mao Q, Li Q, Wang Y, Min F.
    Zhonghua Gan Zang Bing Za Zhi; 2001 Jun 30; 9(3):157-9. PubMed ID: 11412391
    [Abstract] [Full Text] [Related]

  • 8. Interfering with hepatitis C virus IRES activity using RNA molecules identified by a novel in vitro selection method.
    Romero-López C, Barroso-delJesus A, Puerta-Fernández E, Berzal-Herranz A.
    Biol Chem; 2005 Feb 30; 386(2):183-90. PubMed ID: 15843163
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA.
    Lan N, Rooney BL, Lee SW, Howrey RP, Smith CA, Sullenger BA.
    Mol Ther; 2000 Sep 30; 2(3):245-55. PubMed ID: 10985955
    [Abstract] [Full Text] [Related]

  • 13. A peptide derived from RNA recognition motif 2 of human la protein binds to hepatitis C virus internal ribosome entry site, prevents ribosomal assembly, and inhibits internal initiation of translation.
    Pudi R, Ramamurthy SS, Das S.
    J Virol; 2005 Aug 30; 79(15):9842-53. PubMed ID: 16014945
    [Abstract] [Full Text] [Related]

  • 14. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
    Soler M, McHutchison JG, Kwoh TJ, Dorr FA, Pawlotsky JM.
    Antivir Ther; 2004 Dec 30; 9(6):953-68. PubMed ID: 15651754
    [Abstract] [Full Text] [Related]

  • 15. Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme.
    Song MS, Lee SW.
    FEBS Lett; 2006 Sep 18; 580(21):5033-43. PubMed ID: 16949075
    [Abstract] [Full Text] [Related]

  • 16. Human ribosomal protein L18a interacts with hepatitis C virus internal ribosome entry site.
    Dhar D, Mapa K, Pudi R, Srinivasan P, Bodhinathan K, Das S.
    Arch Virol; 2006 Mar 18; 151(3):509-24. PubMed ID: 16195786
    [Abstract] [Full Text] [Related]

  • 17. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing.
    Sullenger BA, Cech TR.
    Nature; 1994 Oct 13; 371(6498):619-22. PubMed ID: 7935797
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.
    Song MS, Jeong JS, Ban G, Lee JH, Won YS, Cho KS, Kim IH, Lee SW.
    Cancer Gene Ther; 2009 Feb 13; 16(2):113-25. PubMed ID: 18758435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.